RxDoctor Payments Data

Alisha Tarter Wilson, PA

Surgical · Somerset, KYNPI 1760629943

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $665, 2.2 times the $307 reported in 2021.

$1,793in general payments, 2019–2025

Across 82 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$358
  • Astellas Pharma US Inc$312
  • Bayer$190
  • Endo USA, Inc.$158
  • Medtronic$137
  • Johnson & Johnson$120
  • plus $518 from 13 others

What the payments were for

  • Food & beverage$1,64392%
  • Education$1508%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,793 in reported general payments places this provider in the 75th percentile of 72 surgical providers in Kentucky.

See all surgical providers in Kentucky

Medicare billing

Part B allowed, 2024
$75,539
Medicare patients
446
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron210$133,829
MyrbetriqMirabegron126$78,704
Solifenacin Succinate130$12,737
Estradiol119$6,659
Doxycycline Monohydrate230$6,275
Methenamine Hippurate70$4,663
Tolterodine Tartrate ErTolterodine Tartrate29$4,358
Trospium Chloride80$4,152
Tamsulosin Hcl359$2,435
Trospium Chloride ErTrospium Chloride13$2,195
NitrofurantoinNitrofurantoin Macrocrystal46$2,126
CefuroximeCefuroxime Axetil164$1,839
Finasteride202$1,501
Bethanechol Chloride22$1,447
Baclofen97$1,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$358$133,829210 claims
Astellas Pharma US IncMyrbetriq$312$78,704126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 72 surgical providers in Kentucky.

Other surgical in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →